ICMR recommends anti-malarial drug Hydroxychloroquine for treating high-risk COVID-19 patients

The Hush Post | 6:17 pm | One-minute read |

The Indian Council of Medical Research (ICMR) has recommended the use of drug Hydroxychloroquine for treating high-risk COVID-19 patients. According to ICMR, the anti-malarial drug can be used under “under exceptional circumstances” in high-risk patients.

Besides, the ICMR has recommended Hydroxychloroquine for asymptomatic healthcare workers involved in the care of suspected or confirmed cases of Covid-19. Also it has suggested the use of the drug for asymptomatic household contacts of laboratory confirmed cases.

ICMR’s Director-General Dr.Balram Bhargava issued a note on the recommendation on Sunday.

ICMR recommends 400mg dosage twice a day, followed by a weekly dose of 400mg for next 7 weeks with meals. ICMR has not recommended the drug for children under 15 years.

Pertinently a global debate is raging on the use of Hydroxychloroquine for treating COVID-19. Western researches have showed that Hydroxychloroquine has proved successful in treatment of patients with coronavirus infection.

Some French scientists have even claimed that a combination of Hydroxychloroquine and Azithromycin is a 100 per cent cure for COVID-19. In India, doctors have given coronavirus patients anti-HIV drugs too.

However, the scientific community has urged caution as research is currently limited as clinical trials of much larger scales need to be conducted to conclusively determine the effectiveness of a drug.

LEAVE A REPLY

Please enter your comment!
Please enter your name here